ATAI is trading 5.2% up at $5.22 after announcing it has dosed the last patient in its Phase 2b Elumina trial of VLS-01 for treatment-resistant depression.
- The trial successfully randomized 156 patients, with topline data results now expected in Q4 2026.
- Investors are encouraged by the progress toward potential Phase 3 development in major depressive disorder, supporting sentiment despite broader market weakness.